Skip to content

US · INDV · DRUG MANUFACTURERS - SPECIALTY & GENERIC

Indivior Pharmaceuticals Inc (INDV) intrinsic value and stock valuation

$36.28as of 2026-11-21 · Mkt cap 4.83B

Data updated · price as of 2026-11-21

Fairly valuedIC value is within 20% of the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Indivior Pharmaceuticals Inc DCF and intrinsic value

InvestorsCraft values INDV with the Chepakovich two-stage DCF model — currently rated fairly valued. How the model works · Run your own DCF prefilled from INDV’s statements →

Indivior Pharmaceuticals Inc Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Drug Manufacturers - Specialty & Generic North Chesterfield, VA 23235 indivior.com

How the business is doing

Fiscal 2016–2025, USD

Revenue
$1.24B+13.9% 5y CAGRd
20162025
Net income
$210M
20162025
Free cash flow
-$-94M
20162025
Total equity
-$-98M
20162025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2016–2025, USD
20252024202320222021
Revenue$1.24B$1.19B$1.09B$901M$791M
Operating income$265M$32M-$-156M-$-81M$213M
Net income$210M$2M-$-129M-$-44M$205M
EPSd$1.64M$15K-$-909.73K-$-316.52K$1.33M
Operating cash flow-$-27M$36M-$-300M-$-4M$353M
Capital expenditure-$-67M-$-31M-$-53M-$-5M-$-34M
Free cash flow-$-94M$5M-$-353M-$-9M$319M
Total assets$1.2B$1.32B$1.77B$1.78B$1.83B
Total debt$351M$375M$283M$277M$286M
Net debt$156M$56M-$-33M-$-501.18M-$-816M
Total equity-$-98M-$-348M-$-191M$51.3M$203M
Cash and short-term investments$195M$320M$410M$897.8M$1.1B
Income statement
20252024202320222021
Revenue$1.24B$1.19B$1.09B$901M$791M
Cost of revenue$246M$231M$174M$151M$127M
Gross profit$993M$957M$919M$750M$664M
Research and development expenses$97M$107M$116M$74M$52M
Selling, general and administrative expenses$634M$618M$569M$469M$431M
Other expenses-$-3M$200M$390M$288M-$-32M
Operating expenses$728M$925M$1.08B$831M$451M
Cost and expenses$974M$1.16B$1.25B$982M$578M
Interest income$22M$23M$43M$19M$4M
Interest expense$45M$41M$35M$29M$26M
Depreciation and amortization$20M$29M$15M$16M$22M
Ebitda$304M$84M-$-99M-$-46M$238M
Operating income$265M$32M-$-156M-$-81M$213M
Total other income/expenses, net-$-26M-$-18M$7M-$-8M-$-23M
Income before tax$239M$14M-$-149M-$-89M$190M
Income tax expense$29M$11M-$-20M-$-44M-$-15M
Net income$210M$2M-$-129M-$-44M$205M
Weighted average shares outstanding$125M$132M$137.3M$139M$145.7M
Weighted average diluted shares outstanding$128M$133M$141.8M$139M$154.2M
Balance sheet
20252024202320222021
Cash and short-term investments$195M$320M$410M$897.8M$1.1B
Net receivables$255M$254M$254M$220M$202M
Inventory$153M$178M$135M$114.6M$95M
Total current assets$652M$839M$1.27B$1.27B$1.44B
Property, plant and equipment, net$170M$139M$124M$85.5M$95M
Goodwill and intangible assets$2M$7M$13M$70M$82M
Long-term investments$28M$26M$41M$98.5M$0.00
Total non-current assets$552M$481M$499M$512.8M$388M
Total assets$1.2B$1.32B$1.77B$1.78B$1.83B
Accounts payable$48M$63M$39M$33M$26M
Short-term debt$39M$28M$12M$11M$11M
Deferred revenue$0.00$0.00$0.00$9.05M$0.00
Total current liabilities$914M$939M$1.29B$1.02B$804M
Long-term debt$312M$347M$271M$266M$275M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$388M$728M$666M$702.8M$825M
Capital lease obligations$22M$42M$34M$37M$44M
Total liabilities$1.3B$1.67B$1.96B$1.73B$1.63B
Common stock$62M$62M$68M$68.4M$70M
Retained earnings-$-243M-$-454M-$-295M$1.31B$1.44B
Accumulated other comprehensive income (loss)-$-30M-$-46M-$-1.35B-$-1.34B$0.00
Total equity-$-98M-$-348M-$-191M$51.3M$203M
Total investments$28M$27M$135M$218.2M$0.00
Total debt$351M$375M$283M$277M$286M
Net debt$156M$56M-$-33M-$-501.18M-$-816M
Cash flow statement
20252024202320222021
Net income$210M$7M-$-126M-$-44M$213M
Depreciation and amortization$20M$28M$15M$16M$22M
Stock-based compensation$26M$24M$21M$16M$11M
Change in working capital-$-257M-$-46M-$-297M$118M$173M
Accounts receivable$3M-$-1M-$-33M-$-21M-$-25M
Inventory$18M-$-43M-$-6M-$-30M-$-3M
Accounts payable$0.00$0.00$0.00$0.00$0.00
Net cash provided by operating activities-$-27M$36M-$-300M-$-4M$353M
Investments in property, plant and equipment-$-66M-$-29M-$-8M-$-5M-$-4M
Acquisitions, net$0.00$0.00-$-129M$0.00$0.00
Net cash used for investing activities-$-66M$69M-$-95M-$-222M-$-14M
Common stock issued-$-3M-$-19M-$-19M-$-8M$1M
Common stock repurchased-$-11M-$-173M-$-33M-$-90M-$-101M
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-30M-$-102M-$-64M-$-101M-$-94M
Net change in cash-$-124M$3M-$-458M-$-328M$244M
Cash at end of period$195M$319M$316M$774M$1.1B
Operating cash flow-$-27M$36M-$-300M-$-4M$353M
Capital expenditure-$-67M-$-31M-$-53M-$-5M-$-34M
Free cash flow-$-94M$5M-$-353M-$-9M$319M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Indivior Pharmaceuticals Inc

        Indivior Pharmaceuticals Inc. operates as a holding company, primarily engaged in the research, production, and distribution of buprenorphine-based prescription medications designed to treat opioid dependence. Its product lineup features key pharmaceuticals such as Suboxone Film, Suboxone Tablet, and Subutex Tablet. The company organizes its business into several geographical regions: the United States, the United Kingdom, and the broader international market. Established on September 26, 2014, its corporate headquarters are located in North Chesterfield, Virginia.

        CEO
        Joseph J. Ciaffoni
        Employees
        833
        Beta
        1.03

        Explore

        Frequently asked questions

        What is the intrinsic value of Indivior Pharmaceuticals Inc (INDV)?

        Indivior Pharmaceuticals Inc (INDV) is currently fairly valued based on the InvestorsCraft IC model — IC value is within 20% of the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is INDV undervalued?

        INDV trades at a price of $36.28 (Nov 21, 2026): fairly valued — IC value is within 20% of the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.